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The lipoglycopeptide antibiotics teicoplanin and
A40926 have proven efficacy against Gram-positive
pathogens. These drugs are distinguished from
glycopeptide antibiotics by N-linked long chain
acyl-D-glucosamine decorations that contribute to
antibacterial efficacy. During the biosynthesis of
lipoglycopeptides, tailoring glycosyltransferases at-
tach an N-acetyl-D-glucosamine to the aglycone,
and this N-acetyl-glucosaminyl pseudoaglycone is
deacetylated prior to long chain hydrocarbon attach-
ment. Here we present several high-resolution crys-
tal structures of the pseudoaglycone deacetylases
from the biosynthetic pathways of teicoplanin and
A40926. The cocrystal structure of the teicoplanin
pseudoaglycone deacetylase with a fatty acid prod-
uct provides further insights into the roles of active-
site residues, and suggests mechanistic similarities
with structurally distinct zinc deacetylases, such as
peptidoglycan deacetylase and LpxC. A unique,
structurally mobile capping lid, located at the apex
of these pseudoaglycone deacetylases, likely serves
as a determinant of substrate specificity.
INTRODUCTION
As the prevalence of antibiotic-resistant bacteria continues to
become a global health concern, the search for novel antimicro-
bials with broad-spectrum efficacy and low toxicity remains
a critical challenge for the biomedical community (Martinez
et al., 2007; Zinner, 2007). The glycopeptide antibiotic vancomy-
cin 1 (Figure 1) (trade names: Vancocyn, Lyphocin) has proven
effective for treatment against infections from resistant, Gram-
positive pathogens (Moellering, 2006), including methicillin-re-
sistant Staphylococcus aureus (MRSA) (Anstead and Owens,
2004; Anstead et al., 2007) and drug-resistant pneumococci
(Cunha, 2006). However, the emergence of vancomycin-resis-
tant bacteria, including vancomycin-resistant enterococci
(Murray, 2000) and vancomycin-intermediate and -resistantChemistry & BiologyS. aureus (VISA and VRSA, respectively) (Hiramatsu et al.,
1997; Sieradzki et al., 1999), threatens this last line of defense
against fatal infections. The lipoglycopeptide antibiotics teico-
planin 2 (trade name: Targocid) (Spencer and Bryson, 1995)
and A40926 4 (a derivative of which is trademarked as Dalbavan-
cin) (Scheinfeld, 2007) have demonstrated minimal toxicity, and
proven efficacy against Gram-positive MRSA and VRSA (Van
Bambeke, 2006). These lipoglycopeptides exert their antimicro-
bial effect in a manner similar to glycopeptides, such as vanco-
mycin, by targeting the N-acyl-D-Ala-D-Ala peptides of peptido-
glycan precursors to inhibit cell wall synthesis in Gram-positive
bacteria (Kahne et al., 2005).
Like the glycopeptide vancomycin, the lipoglycopeptides tei-
coplanin and A40926 are composed of a heptapeptide aglycone
that is further decorated with carbohydrates (Donadio et al.,
2005). Unlike vancomycin, a characteristic modification found
only in lipoglycopeptides is the attachment of an N-acyl-D-glu-
cosamine at position 4 of the heptapeptide aglycone (Goldstein
et al., 1987; Malabarba et al., 1984). Although the heptapeptide
core is thought to be sufficient to target the N-acyl-D-Ala-
D-Ala di-peptide, the carbohydrate and acyl groups contribute
greatly to the antimicrobial efficacy of lipoglycopeptides (Beau-
regard et al., 1995; Wiliams and Bardsley, 1999). In particular,
the hydrophobic acyl chain of theN-acyl-D-glucosamine can an-
chor the antibiotic at the cell membrane, thereby increasing the
local antibiotic concentration at the target site for its activity
(Cooper and Williams, 1999). The increased efficacy of teicopla-
nin against vancomycin-resistant enterococci has been directly
attributed to the hydrophobic acyl chain (Dong et al., 2002),
prompting research efforts toward the design of alkyl derivatives
of glycopeptides with increased antimicrobial properties relative
to the parent compounds. The success of this approach is re-
flected in the fact that telavancin 5, a semisynthetic derivative
of vancomycin that contains a decylaminoethyl appendage (Hig-
gins et al., 2005), and oritavancin 6, a N-alkyl-p-chlorophenyl-
benzyl derivative of chloroeremomycin (Allen and Nicas, 2003),
are both currently in phase III clinical trials for use against
Gram-positive infections. Hence, semisynthetic and genetic ap-
proaches toward N-acyl modification of glycopeptides are of
significant pharmaceutical interest.
The elucidation of the biosynthetic routes for lipoglycopeptide
production by actinomycetes have established the general15, 533–545, June 2008 ª2008 Elsevier Ltd All rights reserved 533
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Antibiotic Pseudoaglycone Deacetylases StructuresFigure 1. Chemical Structures of the Glycopeptide Antibiotics
The structures of vancomycin (1) and chloroeremomycin (3); the lipoglycopeptides teicoplanin (2; shows the A2-5 teicoplanin) and A40926 (4); and two semisyn-
thetic lipoglycopeptide antibiotics that are currently in clinical trials telavancin (5) and oritavancin (6).scheme for N-acyl-D-glucosamine tailoring of the aglycone for
both teicoplanin in Actinoplanes teichomyceticus (Li et al.,
2004; Sosio et al., 2004) and A40926 in Nonomuraea sp. ATCC534 Chemistry & Biology 15, 533–545, June 2008 ª2008 Elsevier Ltd39727 (Sosio et al., 2003). Specifically, the addition of a glucos-
aminemoiety to the hydroxyl group of amino acid 4 by a glycosyl-
transferase (Dbv9 for A40926, and Orf10* for teicoplanin) isAll rights reserved
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Antibiotic Pseudoaglycone Deacetylases StructuresFigure 2. Schematic Illustration of the Steps Involved in the Biosynthesis of Lipoglycopeptide Antibiotics
The linear heptapeptide backbone is synthesized by the nonribosomal peptide synthases (NRPS) and crosslinked by oxidases to yield the core aglycone struc-
ture. A tailoring glycosyltransferase addsN-acetyl-D-glucosamine to amino acid 4, followed by deacetylation by a pseudoaglycone deacetylase prior to acylation
to yield an N-acyl-D-glucosamine. Additional tailoring steps are carried out by methylases and an additional glycosyltransferase to yield the mature antibiotic.followed by N-acylation at the glucosamine by an acyltransfer-
ase (Orf8 for A40926, and Orf11* for teicoplanin) (Kruger et al.,
2005; Li et al., 2004; Sosio et al., 2003; Figure 2). The glycosyl-
transferases involved are shown to have broad specificity, and
can utilize either an amino sugar (UDP-D-glucosamine) or an ac-
tivated amino sugar (UDP-N-acetyl-D-glucosamine) as a sub-
strate, in vitro (Kruger et al., 2005; Li et al., 2004). However, as
bacteria cannot produce UDP-D-glucosamine as a primary me-
tabolite, the in vivo substrate for the Orf10* glycosyltransferase
was established as UDP-N-acetyl-D-glucosamine (Li et al.,
2004). Prior to acylation by Orf11*, the N-acetyl-glucosaminyl
pseudoaglycone must be deacetylated to yield a free 20-amine
(Figure 2). Bioinformatic analysis identifies putative deacetylase
genes within the biosynthetic gene clusters for lipoglycopeptide
antibiotics, and the gene products Orf2* and Dbv21 are shown to
encode pseudoaglycone deacetylases for the maturation of
tecioplanin and A40926, respectively (Ho et al., 2006; Truman
et al., 2006). Homologs of these proteins are also encoded in
the biosynthetic gene cluster for the aminoglycoside antibiotic,
butirosin, as the BtrD gene product, which was initially reported
to harbor nucleotidyltransferase activity, has more recently been
functionally reclassified as a homolog of the pseudoaglycone
deacetylases (Truman et al., 2007).Chemistry & BiologyThe pseudoaglycone deacetylases Orf2* and Dbv21 are
roughly the same molecular mass (roughly 30,000 Da) and share
65% sequence identity with each other. Biochemical in vitro ac-
tivity has been established for recombinant forms of both Orf2*
(deacetylation of N-acetyl-D-glucosaminyl teicoplanin pseudoa-
glycone) and Dbv21 (deacetylation of N -acetyl-D-glucosaminyl
A40926 pseudoaglycone) (Ho et al., 2006; Truman et al., 2006).
The two enzymes show moderate promiscuity for substrate,
and Dbv21 can also acceptN-acetyl-D-glucosaminyl teicoplanin
pseudoaglycone (but not teicoplanin) as a substrate. Interest-
ingly, Orf2* cannot accept N-acetyl-D-glucosamine or N-ace-
tyl-D-glucosamine-UDP as substrate, which suggests that the
teicoplanin aglycone is important for substrate recognition
(Ho et al., 2006; Truman et al., 2006). Finally, Orf2* is also capa-
ble of removing the acyl group from mature teicoplanin to yield
a precursor with a free 20-amine, which can then be regio-specif-
ically modified for the production of novel glycopeptide anti-
biotics (Truman et al., 2006).
The pseudoaglycone deacetylases share modest sequence
and functional similarities with MshB, a zinc-dependent metallo-
protein that deacetylatesN-acetyl-D-myo-inosityl-2-deoxy-a-D-
glucopyranoside during the production ofmycothiol in actinomy-
cetes (Newton et al., 2000, 2006; Rawat et al., 2003). The crystal15, 533–545, June 2008 ª2008 Elsevier Ltd All rights reserved 535
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Antibiotic Pseudoaglycone Deacetylases Structuresstructure of MshB reveals a structural similarity to the glycogen
phosphorylase/glycosyl transferase superfamily of protein folds
(Maynes et al., 2003; McCarthy et al., 2004). A single zinc ion is
located at the active site, where it is coordinated by protein res-
idues His-13, Asp-16, and His-147, with two water molecules
completing a square pyramidal coordination geometry. Binding
of substrate is thought to displace the first water molecule, and
the second metal-activated water (or hydroxide) serves as the
nucleophile for the hydrolysis reaction. Residues that flank the
metal binding site are implicated to act as a general base or to
stabilize the tetrahedral intermediate during hydrolysis (Maynes
et al., 2003; McCarthy et al., 2004).
The structure of MshB does not serve as a valid template for
understanding the mechanism of the pseudoaglycone deacety-
lases. Although the 30% sequence identity likely indicates
a common topology, distinct features of the active site cannot
be successfully predicted due to the low sequence similarity
shared between these proteins. Additionally, although divalent
metal ions are critical to the function of Orf2*, the identity of
the metal has not been determined, as different divalent ions
only show slight difference in catalytic efficiency. In addition,
the presence of high concentrations of divalent zinc is inhibitory
to deacetylase activity, consistent with similar effects previously
observed for zinc-dependent metalloproteases (Truman et al.,
2006). However, the mechanism for zinc inhibition of the pseu-
doaglycone deacetylases has yet to be established.
In order to provide a molecular framework for understanding
the mechanism of these enzymes, we present several high-res-
olution crystal structures of pseudoaglycone deacetylases. We
have determined the structure of the teicoplanin deacetylase
Orf2* to 1.6 A˚ resolution, and the A40926 deacetylase Dbv21
to 2.1 A˚ resolution. In order to elucidate the binding site for the
lipoglycopeptide long chain fatty acid, we have determined the
2.1 A˚ resolution cocrystal structure of Orf2* bound to a product
decanoic acid. In order to understand the molecular basis for
Zn2+ inhibition of Orf2*, we present the structure of Orf2* bound
to excess zinc. Our structures complement previous biochemi-
cal data to provide a molecular understanding of the mechanism
of these pseudoaglycone deacetylase structures, and will be
essential in biotransformation applications for developing novel
lipoglycopeptide antibiotics.
RESULTS AND DISCUSSION
Overall Structure
The crystal structure of the teicoplanin deactylase Orf2* was de-
termined to 1.6 A˚ resolution with single-wavelength anomalous
scattering from crystals grown from selenomethionine incorpo-
rated protein. Residues Thr-8 through Ser-273 (out of a total of
273 residues) could be modeled without any interruptions, and
the structure has been refined to an R factor/free R factor of
19.4%/22.3% (Figure 3A). The structure of the A40926 deacety-
lase Dbv21 was determined to 2.1 A˚ resolution by molecular re-
placement with the refined coordinates of Orf2* as a search
probe (Figure 3B). The first six amino acids of the protein and
an internal loop consisting of residues 102–124 have not been
modeled due to disorder. The structure has been refined to an
R factor/free R factor of 20.9%/25.2% (see Table 1 for relevant
phasing and refinement statistics).536 Chemistry & Biology 15, 533–545, June 2008 ª2008 Elsevier LtThe overall structures of Orf2* and Dbv21 are similar, as
expected from the 65% sequence similarity shared between
the two proteins (Figure 3C). The root-mean-square deviation
(rmsd) between the polypeptides is 1.2 A˚ over 240 aligned
main chain atoms. The overall folds of the two pseudoaglycone
deacetylases consist of a single a/b domain with large loops that
interconnect the secondary structure elements. Prior studies
have established that Orf2* can deacetylate teicoplanin (Truman
et al., 2006), suggesting that the acyl chain of the mature antibi-
otic can be accommodated in a hydrophobic pocket. Detailed
structural comparisons of Orf2* and Dbv21 in the vicinity of the
active site are restrictive, as a loop that caps the active site is
disordered in the structure of the latter enzyme (see below for
details).
A structure-based similarity search of Orf2* with a Dali (Holm
and Sander, 1995) search engine queried against the Protein
Data Bank (Berman et al., 2000) identifies MshB as the closest
structural homolog (Z score = 18.3; rmsd = 2.7 A˚ over 194 aligned
residues) (Maynes et al., 2003; McCarthy et al., 2004). Modest
structural similarity is also noted with various glycosyltrans-
ferases and other proteins of the glycogen phosphorylase/glyco-
syl transferase (GPGTF) superfamily of folds (Liu andMushegian,
2003). The closest structural homologs of the pseudoaglycone
deacetylases also utilize substrates that contain a substituted
N-acetyl-D-glucosamine, suggesting a common evolutionary
ancestry of the active-site structural elements. Although the
core topological elements are similar between the pseudoagly-
cone deacetylases, MshB, and glycosyltransferases of the
GPGTF superfamily, only the pseudoaglycone deacetylases
and MshB are single-domain metalloproteins containing a sub-
strate binding site that flanks the zinc ion. In contrast, members
of the GPGTF superfamily contain a tandem repeat of this archi-
tecture, do not contain any metal ions, and harbor a substrate
binding site at the interdomain cleft.
Active-Site Architecture
In the structures of each of the pseudoaglycone deacetylases,
a single divalent metal ion is situated at the base of a 16 A˚ cavity
near the center of the molecule (Figures 3A and 3B). The metal is
coordinated by protein residues His-16 (Zn2+–Nd1, distance =
2.09 A˚), Asp-19 (Zn2+–Od2, distance = 2.12 A˚), and His-164
(Zn2+–N31, distance = 2.14 A˚) (Orf2* numbering) (Figure 4A).
The identity of the metal is confirmed to be zinc based on metal
analysis, and results from X-ray fluorescence scans. Anomalous
difference Fourier maps, calculated with phases from the final
refined model (minus all metal atoms), and coefficients from
Bijvoet differences from data collected at the zinc absorption
edge (l = 1.27819 A˚), shows significant spherical density at the
zinc binding site (Figure 4B). Additionally, the coordination ge-
ometry of the metal is similar to that observed for zinc ions in
other metalloenzymes. Two solvent molecules (distances from
Zn2+ of 2.00 and 2.11 A˚) complete the coordination sphere to
yield a square pyramidal coordination geometry for the zinc
ion (Figure 4C). The disposition of the metal ion deep within the
active site cavity explains why the addition of a large chelator
EDTA had minimal affect on enzyme activity (Truman et al.,
2006).
Adjacent to the active site, a stretch of continuous electron
density, which has been interpreted as a polyethylene glycold All rights reserved
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Antibiotic Pseudoaglycone Deacetylases StructuresFigure 3. Structures of Pseudoaglycone Deacetylases Orf2* and Dbv21
(A) Ribbon diagram derived from the 1.6 A˚ resolution structure of the teicoplanin pseudoaglycone deacetylase Orf2* shown in a color ramp fromblue to green. The
catalytically requisite zinc ion is shown as a red sphere and the location of the capping loop is noted.
(B) Ribbon diagram derived from the 2.1 A˚ resolution structure of the A40926 pseudoaglycone deactylase Dbv21 shown in a color ramp from yellow to purple.
Electron density for the capping loop is ill defined, and residues 102–124 have not been modeled due to disorder.
(C) Structure-based sequence alignment of enzymes related to the pseudoaglycone deactylases. Note that, while the gene clusters for the biosynthesis of bal-
himycin (A. balhimycina) and chloroeremomycin (A. orientalis) encode for gene products with 60% sequence identity, neither antibiotic contains a glucosaminyl
group. In addition, the gene product from A. orientalis is shown to harbor nucleotidyltransferase activity.heptamer, occupies the hydrophobic acyl chain binding pocket
(Figure 4A). Additional protein residues near the metal center
include Asp-18, His-161, Asp-163, and Tyr-190 (Figure 4A).Chemistry & BiologyBy analogy to chemically similar residues that are found near
the active sites of other zinc-dependent deacetylases, Asp-
18 is the general base that activates one of the zinc-bound15, 533–545, June 2008 ª2008 Elsevier Ltd All rights reserved 537
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Antibiotic Pseudoaglycone Deacetylases StructuresTable 1. Data Collection, Phasing, and Refinement Statistics
SeMet Orf2* Orf2*-Zinc Orf2*-Decanoate Dbv21
Data collection
Space group P21 P21 P21 P41212
Cell dimensions
a, b, c (A˚) 42.2, 64.3, 50.5 41.3, 64.3, 49.9 41.7, 64.5, 50.5 62.9 62.9 159.9
a, b, g () 90.0, 99.2, 90.0 90.0, 98.9, 90.0 90.0, 98.9, 90.0 90.0, 90.0, 90.0
Resolution (A˚) 50.0–1.6 (1.67–1.60)a 50–2.0 (2.07–2.0)a 50–1.8 (1.86–1.8)a 50–2.07 (2.15–2.07)a
Rsym (%)
b 4.3 (28.8) 4.4 (21.8) 4.6 (10.6) 8.5 (68.2)
I/s(I) 34.5 (4.8) 33.6 (5.3) 23.8 (9.2) 15.9 (3.1)
Completeness (%) 98.4 (94.3) 99.3 (93.5) 97.3 (92.2) 96.5 (85.3)
Redundancy 4.2 (4.1) 4.0 (3.2) 2.8 (2.5) 8.7 (5.5)
jFHj/e (acentric) 1.67
FOM/DM FOMc 0.37/0.90
Refinement
Resolution (A˚) 25.0–1.6 25.0–2.0 25.0–1.8 25.0–2.1
No. of reflections 32,604 16,079 22,587 18,476
Rwork/Rfree (%/%)
d 19.4/22.4 19.8/24.1 17.6/22.0 20.9/25.2
No. of atoms
Protein 2103 2074 2074 1865
Solvent 241 87 251 94
Zinc ion 1 5 1 1
Ligand 12
Mean B value (A˚2)
Protein 25.1 37.5 27.5 52.4
Solvent 37.7 39.0 41.4 52.7
Zinc ion 18.5 44.4 23.9 45.9
Ligand — — 39.8 —
Rmsd
Bond lengths (A˚) 1.129 1.145 1.179 1.384
Bond angles () 0.009 0.009 0.009 0.014
Abbreviations: acentric, acentric reflections; e, residual lack of closure error; FH, structure factor amplitude of the heavy atom derivative; FOM, figure of
merit.
a Highest resolution shell is shown in parenthesis.
b Rsym = S jIi  < Ii > j S Ii, where Ii = intensity of the ith reflection and < Ii > = mean intensity.
cMean figure of merit before and after density modification.
d R factor = S (jFobsj  kjFcalcj)/S jFobsj and Rfree is the R value for a test set of reflections consisting of a random 5% of the diffraction data not used in
refinement.water molecules for nucleophilic attack on the acetate, and
His-161 and Tyr-190 act to stabilize the negative charge on
the tetrahedral intermediate during catalysis. Interestingly, the
electron density around Tyr-190 in the structures of both pseu-
doaglycone deacetylases suggests mobility, and two con-
formers of this residues can be readily modeled in the 1.6 A˚
resolution structure of unliganded Orf2*. Presumably, substrate
binding orients and stabilizes one conformer of Tyr-190 for ef-
fective stabilization of the oxyanion intermediate. Based on its
location in the vicinity of the other catalytic residues, and the
presumed function of equivalent residues in other deacety-
lases, Asp-163 likely accepts a proton from the imidazolium
of His-161 and orients this residue for effective stabilization
of the tetrahedral oxyanion intermediate and its flanking transi-
tion states.538 Chemistry & Biology 15, 533–545, June 2008 ª2008 Elsevier LtIdentification of a Binding Site for the Hydrophobic
Acyl Chain
Various attempts to obtain cocrystal structures of Orf2* with sub-
strate teicoplanin pseudoaglycone have not been successful.
Consistent with prior biochemical data (Truman et al., 2006),
we observe that Orf2* can also accommodate mature teicopla-
nin as a substrate, and the catalytic efficiency for the removal
of the acyl chain byOrf2* ismuch lower than for the deacetylation
reaction. Unfortunately, attempts to produce cocrystals of Orf2*
bound to deacylteicoplanin have also been unsuccessful. Since
the hydrophobic acyl chain is a product of the deacylation reac-
tion, we also attempted cocrystallization of Orf2* with various
long chain fatty acids. We presume that the fatty acid would
bind to the enzyme at the same location as the acyl chain substit-
uent of substrate teicoplanin, as has been observed in crystald All rights reserved
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Antibiotic Pseudoaglycone Deacetylases StructuresFigure 4. Close-Up View of the Active Site
of Orf2*
(A) The zinc ion is shown in green, and catalytically
relevant residues are shown as ball and stick
models and labeled accordingly. Note that
Tyr-190 occupies multiple conformations in the
structure of the native enzyme. Amolecule of poly-
ethylene glycol (derived from the crystallization
medium) occupied the hydrophobic binding site,
and is shown in pink.
(B) Anomalous difference Fourier electron density
map calculated with phases from the final refined
model of Orf2* minus the metal atom and coeffi-
cients jF+j  jFj, corresponding to Bijvoet differ-
ences from data collected at the zinc absorption
edge (l = 1.27819 A˚). The contour levels are 4s
(blue mesh) and 8s (purple mesh) above back-
ground.
(C) Stereo view of electron density maps calcu-
lated with Fourier coefficients Fobs  Fcalc with
phases derived from the final refined model of un-
liganded Orf2* minus active-site features. The first
mapwas calculated by omitting the coordinates of
the zinc ion prior to one round of crystallographic
refinement, and is contoured at 5s (blue mesh)
and 15s (purple mesh). The second map was cal-
culated by omitting the nonprotein zinc ligands,
and is shown contoured at 3.5s (salmon mesh).
The final refined coordinates are superimposed
with the zinc ion colored green, and the zinc-
bound solvent molecules are colored red.structures of other zinc-dependent deacetylases (Whittington
et al., 2003). We were successful in obtaining the structure of
Orf2* bound to decanoic acid to 1.8 A˚ resolution, and this struc-
ture has been refined to an R factor/free R factor of 17.6%/
22.0% (see Table 1 for relevant refinement statistics).
The structure of the Orf2*-decanoic acid binary complex
shows electron density adjacent to the zinc ion at the active
site (Figure 5A). Although the density is somewhat discontinuous
at the tail end of the hydrocarbon chain, the features are consis-
tent with that of a bound decanoic acid ligand. In contrast to the
bindingmode of ligands observed in other cocrystal structures of
other zinc-deacetylases, the carboxylate of the fatty acid does
not engage the metal ion in a bidentate fashion. Rather, the elec-
tron density is consistent with one of the carbonyl oxygens
displacing the presumptive nucleophilic water to engage in an
inner-sphere coordination with zinc (zinc-oxygen distance =
2.16 A˚). The second solvent molecule is not displaced (zinc-
oxygen distance = 2.01 A˚), and the pentacoordinate geometry
at the metal is retained.
The hydrocarbon chain of the fatty acid is packed against one
surface of the active-site cleft, where it engages in van derWaals
interactions with hydrophobic residues Met-59, Trp-63, Ile-99,
Leu-119, and Val-121 (Figure 5A). A number of polar residues
can also be located along this cleft; most notably, Arg-75 and
Asp-97. In the cocrystal structure of the related MshB deacety-
lase, a molecule of b-octylglucopyranoside is bound in the vicin-
ity of equivalent residues, and this has been interpreted to sug-
gest that these residues are involved in the recognition of the
sugar moiety of the substrate. While Asp-97 may indeed play
a role in sugar recognition, the location of Arg-75 is too distant
to support a role in substrate recognition. By analogy to theChemistry & Biologymechanism of peptidoglycan deacetylase, the likely role of
Arg-75 is to orient the general base Asp-18. Inferences on the
role of this residue based on the MshB-b-octylglucopyranoside
structure are difficult as: (1) the position of the bound b-octylglu-
copyranoside is not consistent between the two molecules of
MshB in the crystallographic asymmetric unit of the cocrystal
structure; (2) the structure in question lacks the catalytically
requisite zinc ion, suggesting an unproductive binding mode
for b-octylglucopyranoside; and (3) modeling of the sugar moiety
of the teicoplanin pseudoaglycone onto the position of the
b-octylglucopyranoside in the MshB cocrystal structure would
not allow the acetyl group to be positioned in the vicinity of the
zinc ion. Hence, Arg-75 is not directly involved in engaging
the sugar moiety, and likely serves the other role of positioning
the catalytic base.
Molecular Basis for Zinc Inhibition
In order to identify the requisite for a metal cofactor for pseudoa-
glycone deacetylase activity, the effects of various divalentmetal
ions on the activity of Orf2* were measured by Truman et al.
(2006). The addition of a range of divalent metals has little effect
on enzyme activity, suggesting either that the enzyme copurifies
with a boundmetal that is difficult to displace, or that enzyme ac-
tivity is independent of metal cofactors. Addition of stoichiomet-
ric excess of zinc is shown to be inhibitory, and 3 mM total zinc
ion completely abolishes deacetylase activity, as observed with
several other zinc-dependent metalloenzymes. Hence, the lack
of catalytic enhancement upon addition of exogenous divalent
metal ions is likely a consequence of the fact that the catalytically
requisite zinc ion is held tightly at the active site, is not disrupted
during purification, and can not be disengaged by large chelating15, 533–545, June 2008 ª2008 Elsevier Ltd All rights reserved 539
Chemistry & Biology
Antibiotic Pseudoaglycone Deacetylases StructuresFigure 5. Close-Up Views of the Active Sites
of the Orf2*-Decanoic Acid and Orf2*-Zinc
Complexes
(A) Stereo view of electron density maps calcu-
lated with Fourier coefficients Fobs  Fcalc with
phases derived from the refined 1.8 A˚ resolution
structure of the Orf2*-decanoic acid complex.
The first map was calculated with the coordinates
for the fatty acid being omitted prior to one round
of crystallographic refinement, and is contoured at
2.5s (blue mesh) and 8s (orange mesh). The sec-
ond map was calculated by omitting the coordi-
nates of the zinc-bound solvent molecule, and is
contoured at 3s (purple mesh). The final refined
coordinates are superimposed, and the zinc ion
is shown as a green sphere, the zinc-bound sol-
vent as a red sphere, the fatty acid is shown with
carbon atoms colored pink, and oxygen atoms
are colored red.
(B) Stereo view of electron density maps calcu-
lated with Fourier coefficients Fobs  Fcalc with
phases derived from the refined 2.0 A˚ resolution
structure of the Orf2*-zinc complex. The map is
calculated with the coordinates of the zinc ions
and the nonprotein zinc ligands omitted prior to
one round of crystallographic refinement, and is
contoured at 4s (blue mesh) and 10s (purple
mesh). The final refined coordinates of the com-
plex are superimposed, with the zinc ion shown
as a green sphere, the sulfate ion shown with the
sulfur atoms colored pink, and the oxygen atoms
colored red.agents. In order to elucidate the molecular basis for zinc-medi-
ated inhibition of the pseudoaglycone deacetylases, we deter-
mined the structure of Orf2* grown in the presence of 10 mM
zinc sulfate to 2.0 A˚ resolution. The structure has been refined
to an R factor/free R factor of 19.8%/24.1% (see Table 1 for rel-
evant refinement statistics).
The structure reveals a number of electron-rich, spherical fea-
tures in difference Fourier maps within the vicinity of the active
site, which have been modeled as zinc ions (Figure 5B). The po-
sition and coordination geometry of the native zinc ion remains
intact in the zinc-inhibited structure. However, the electron den-
sity at the nonprotein zinc ligand suggests that the zinc-bound
solvent molecule has been replaced by a sulfate anion. Addition-
ally, a second zinc ion is situated at a distance of 5.8 A˚ away
from the native zinc, where it is coordinated by protein ligands
His-16 (Zn2+–N32, distance = 2.09 A˚), Asp-97 (Zn2+–Od1, dis-
tance = 1.94 A˚), and Asp-163 (Zn2+–Od2, distance = 1.84 A˚),
with another sulfate anion completing the coordination geome-
try. Both metals share a common ligand, with Nd1 of His-16 co-
ordinating to the native zinc and N32 of the same residue coor-
dinating to the inhibitory metal. Such bridging coordination
interactions with binuclear zinc centers are rare, and have only
been previously observed in the structures of phosphorylcholine
esterase (in which an aspartate bridges two zinc ions) (Hermoso
et al., 2005) and superoxide dismutase (in which a histidine imi-
dazolate bridges the zinc and copper ions) (Djinovic et al., 1992).
The tetrahedral coordination of the inhibitory zinc ion at an alter-
nate site is reminiscent of the binuclear zinc cluster observed in
the structure of zinc-inhibited forms of zinc proteases (Gomez-540 Chemistry & Biology 15, 533–545, June 2008 ª2008 Elsevier LtdOrtiz et al., 1997; Holland et al., 1995) and of the zinc-depen-
dentUDP-(3-O-(R-3-hydroxymyristoyl))-N-acetylglucosaminede-
acetylase LpxC (Whittington et al., 2003). However, the 5.87 A˚
metal separation distance observed in the structure of zinc-
inhibited Orf2* is significantly larger than the typical separation
distances of 3.3 A˚ observed in other binuclear zinc clusters
(Christianson, 1991). This larger separation observed in Orf2*
is a consequence of the fact that a common coordinating resi-
due (His-16) is interposed between the native and inhibitory
binding sites.
By analogy to the mechanism of zinc inhibition of other zinc
proteases and deacetylases, themechanism of inhibition is likely
due to steric exclusion of substrate from the active site. For ex-
ample, the structure of the LpxC deacetylase bound to a sub-
strate analog inhibitor TU-514 shows that the nitrogen atom of
the hydroxamate occupies a location similar to that of the inhib-
itory zinc ion (Coggins et al., 2005; Gennadios et al., 2006). Like-
wise, the structure of zinc-inhibited thermolysin reveals that the
inhibitory zinc occupies the presumed position of the carbonyl
oxygen of the scissile peptide bond (Holland et al., 1995). In
each of these structures, the inhibitory zinc ion is engaged by
residues that facilitate catalysis by stabilizing the charge on the
tetrahedral intermediate during catalysis. In the structure of
zinc-inhibited Orf2*, active-site residue His-161 is situated adja-
cent to the inhibitory zinc ion, and this residue similarly acts as an
electrostatic catalyst in pseudoaglycone deacetylation. Partici-
pation of Asp-97 in coordinating the inhibitory zinc ion is also
consistent with the proposal that this residue participates in rec-
ognition of the sugar group of the pseudoaglycone.All rights reserved
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The mechanistic proposal is based on inferences drawn from the crystallographic results presented here and by analogy to the proposed mechanisms for the
mechanistically related, but structurally divergent, deacetylases LpxC and CE-4 family peptidoglycan deacetylase.Proposed Catalytic Mechanism
The crystal structures of the pseudoaglycone deacetylases and
their ligand complexes presented here suggest a mechanism
consistent with those of other zinc-dependent deacetylases
(Figure 6). In particular, a pentacoordinate zinc ion resides at
the base of the active site, where it is ligated by enzyme residues
His-16, Asp-19, and His-164, with twowater molecules complet-
ing the coordination sphere. The carbonyl oxygen of the sub-
strate displaces one of the two water ligands, and polarization
of the oxygen atom of the carbonyl by the zinc activates the car-
bon atom for nucleophilic attack. The catalytic zinc ion also po-
larizes the second water molecule, promoting deprotonation by
the general base Asp-18, and facilitating nucleophilic attack of
this water at the scissile amide linkage of the substrate. Arg-75
orients and polarizes the carboxylate side chain of Asp-18 for
its role as the catalytic base. The resulting tetrahedral oxyanion
intermediate and the flanking transition states are stabilized by
the zinc ion, the imidazolium of His-161, and by Tyr-190. Effec-
tive electrostatic catalysis by His-161 is provided by stabilization
of the imidazolium by the carboxylate side chain of Asp-163.Chemistry & BiologyAsp-18 then serves as a proton donor to the leaving amino group
to generate the reaction products.
One noteworthy distinction in the proposed deacetylation
mechanism of the pseduoaglycone deacetylases concerns the
role of Tyr-190 in oxyanion stabilization. Tyr-190 is not con-
served between the pseudoaglycone deacetylases and the
structurally related zinc deacetylase MshB. However, the
three-dimensional structures of MshB show an equivalent tyro-
sine residue situated in a similar position (Maynes et al., 2003;
McCarthy et al., 2004). In particular, the a helix that harbors
Tyr-190 is deleted in MshB, but a tyrosine residue (Tyr-142) lo-
cated at the apex of a neighboring a helix is oriented in a confor-
mation similar to that of Tyr-190 in Orf2*. In the crystal structure
of the structurally distinct Streptococcus pneumoniae peptido-
glycan deacetylase (Blair et al., 2005), a tyrosine residue, Tyr-
367, is situated proximally to the supposed location of the oxy-
anion of the tetrahedral intermediate. Mutation of this residue
to alanine impairs catalytic activity, suggesting a direct role in
catalysis. Thus, although the identity of Tyr-190 is not conserved
between the pseudoaglycone deacetylases and MshB (Maynes15, 533–545, June 2008 ª2008 Elsevier Ltd All rights reserved 541
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Antibiotic Pseudoaglycone Deacetylases Structureset al., 2003; McCarthy et al., 2004), structural analysis identifies
equivalent tyrosine residues at similar locations.
Functional Similarity to Other Zinc-Dependent
Deacetylases
The pseudoaglycone deacetylases share notable mechanistic
similarities with a number of distinct zinc-dependent deacety-
lases, despite the lack of any appreciable sequence similarity
and topologically distinct three-dimensional structures. Each of
these enzymes uses a near-identical constellation of active-
site residues to carry out deacetylation of a substrate that
contains an N-acetylglucosamine moiety. In particular, the zinc-
dependent UDP-(3-O-(R-3-hydroxymyristoyl))-N-acetylglucos-
amine deacetylase LpxC (Hernick et al., 2005; McClerren et al.,
2005; Whittington et al., 2003), the CE-4 family peptidoglycan
deacetylase from S. pneumoniae (Blair et al., 2005), and the
pseudoaglycone deacetylases all contain the following features:
(1) an active-site pentacoordinate zinc ion that is (2) flanked by
a highly conserved aspartic acid that participates in acid/base
chemistry, and (3) a histidine, stabilized in the imidazolium form
by an aspartic acid, which participates in electrostatic stabiliza-
tion of the oxyanion of the tetrahedral intermediate. In addition,
the peptidoglycan deacetylases (Blair et al., 2005), MshB
(Maynes et al., 2003;McCarthy et al., 2004), and the pseudoagly-
cone deacetylases each contain a tyrosine residue that flanks
the histidine imidazolium and is poised to further serve in electro-
static stabilization of the tetrahedral intermediate. In this subset
of zinc-dependent deacetylases, an arginine residue orients and
polarizes the carboxylate side chain of the aspartic acid catalytic
base. The overall conservation of active-site features among
these enzymes, in spite of their structurally distinct topologies,
suggests that these zinc-dependent deacetylases are the prod-
uct of convergent evolution.
It is interesting to note that the crystal structure of zinc-in-
hibited LpxC reveals a saturated fatty acid molecule, interpreted
as myristic acid, in a hydrophobic tunnel adjacent to the zinc ion
(Whittington et al., 2003). The fatty acid hydrocarbons in the
Orf2*-decanoic acid binary complex similarly occupy a hydro-
phobic site near the zinc. However, in contrast to the myristate
in the LpxC structure, which does not bind to the native zinc
ion (Whittington et al., 2003), one of the carbonyls of the dec-
anoic acid carboxylate coordinates directly to the zinc in Orf2*.
A Unique Capping Loop Implicated in Substrate Binding
Although the pseudoaglycone deacetylases share some topo-
logical similarities with MshB, a notable distinction is the inser-
tion of a large loop region (residues Asp-97 through Ser-128) in
Orf2* and Dbv21 (Figure 3A). This surface-exposed loop covers
the active site, and is situated on the opposing end of the hydro-
phobic, fatty acid binding pocket. The polypeptide chain in the
loop region in the Orf2* structure is mobile, as evidenced by
the higher average thermal (B) factors for residues within this
loop compared to those for the rest of the protein. Moreover,
this loop is not observed in the structure of Dbv21, indicating sig-
nificant disorder of this region in this structure (Figure 3B). Given
that this loop is present only in the amino acid sequences of the
pseudoaglycone deacetylases, and is located atop the active-
site cavity, it is likely that the loop may be a determinant for inter-
actions with the pseudoaglycone substrate. In order to test this542 Chemistry & Biology 15, 533–545, June 2008 ª2008 Elsevier Ltdhypothesis, we examined the integrity of Orf2* with limited
proteolysis, in the absence and presence of substrate, with the
nonspecific protease chymotrypsin.
A time-course analysis of digestion pattern with substoichio-
metric quantities of chymotrypsin (1:500 ratio of protease:Orf2*)
reveals that full-length Orf2* is rapidly cleaved into two fragments
(Figure 7B). Mass spectrometric analysis of the fragments shows
that cleavage takes place between residues Tyr-100-Arg-101
and His-124-Ser-125, located at the two ends of the active-site
capping loop. Incubation of Orf2* with an excess of substrate
teicoplanin prior to proteolysis affords significant protection of
polypeptide, suggesting that this capping loop is sequestered
upon substrate binding. The amino acid sequences for Orf2*
andDbv21 share 65% identity, but show lower sequence similar-
ities between residues encoded in the capping loop. If the
capping loop does indeed interact with the substrate, this
divergence may be a consequence of having to accommodate
the minor difference in the chemical structures between
Figure 7. Possible Role for the Capping Loop in Interactions with
Substrate
(A) Surface representation of the structure of Orf2* illustrating the proximity of
the capping loop to the active site. The capping loop spanning residues Arg-
101 through His-124 is shown in red, and residues Val-113 through Gln-117,
located at the tip of the loop, are shown in yellow. The zinc ion is shown as
a green sphere.
(B) Protease accessibility of the capping loop in the presence and absence of
substrate. Purified recombinant Orf2* was incubated with sequencing-grade
chymotrypsin at a ratio of 500:1 (enzyme:protease) in the presence (lanes 2–
6) and absence (lanes 8–12) of teicoplanin, and equal volumes of the reaction
were quenched at the designated time points. Addition of the substrate affords
significant protection of the capping loop, suggesting that this loop is seques-
tered by the binding of substrate.All rights reserved
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N-acetyl-D-glucosaminyl A40926 pseudoaglycone. Additional
insights into any potential roles of the capping loop inmodulation
substrate specificity are limited by the fact that the capping loop
is disordered in the Dbv21 structure. Further investigation, such
as altering the capping loops between Orf2* and Dbv21, is nec-
essary to determine whether substrate specificity can be swap-
ped by altering the identity of the capping loop.
Homologs of the pseudoaglycone deacetylases can also be
found in gene clusters for natural products that do not contain
a derivatized glucosaminyl moiety. For example, the gene clus-
ters for the biosynthesis of balhimycin (Amycolatopsis balhimy-
cinaDSM5908) (Pelzer et al., 1999) andchloroeremomycin (Amy-
colatopsis orientalis NRRL 18098) (van Wageningen et al., 1998)
contain ORFs that encode for polypeptides with 60% sequence
identity to the pseudoaglycone deacetylases. However, neither
of these natural products contains a glucosaminyl group, and
the polypeptide from the chloroeremomycin cluster is demon-
strated to have thymidyltransferase activity (Ho et al., 2006). A
multiple-sequence alignment of these ORFs with the pseudoa-
glyconedeacetylases shows significant conservation throughout
the entire length of the polypeptide, except for the residues in the
capping loop (Figure 3C). Hence, it seems that these highly sim-
ilar polypeptides have been adapted to carry out entirely different
enzymatic chemistry by alteration of the residues in the active-
site capping loop that is likely involved in substrate engagement.
SIGNIFICANCE
The efficacy of lipoglycopeptide antibiotics against life-
threatening infectionscausedbyGram-positivemultidrug-re-
sistant bacteria is attributed, in part, to their characteristic
N-acyl-D-glucosamine group. Biosynthetic approaches to-
ward the production of lipoglycopeptideswith novel acyl sub-
stituents have received significant interest as avenues for the
developmentofnewantibiotics.Theelucidationof thebiosyn-
thetic routes for lipoglycopeptide production has established
thatN-acetyl-D-glucosamine is attached to the aglycone, and
must be deacetylated prior to addition of the acyl group. The
crystal structures of the teicoplanin and A40926 pseudoagly-
cone deacetylases presented here establish these enzymes
as zinc-dependent deacetylases, and provide insights into
themolecularbasisofsubstrate recognitionandmetallo-inhi-
bition. Despite the lack of any structural homology, these en-
zymes use a similar subset of active-site residues to that of
the zinc-dependent deacetylases LpxC, and peptidoglycan
deacetylase, suggesting that they are the products of conver-
gent evolution. A unique capping loop shown in these struc-
tures is suggested to harbor determinants of substrate spec-
ificity, and novel specificities may likely be engineered by
altering this loop. These structural results will likely further
rational redesign efforts aimed toward the semisynthetic
production of novel lipoglycopeptide derivatives.
EXPERIMENTAL PROCEDURES
Cloning, Protein Expression, and Purification
Bacterial strains were purchased from the American Tissue Culture Collection
and the full-length cDNA fragments encoding the two pseudoagylcone deace-Chemistry & Biologytylases, Dbv21 and Orf2*, were amplified by polymerase chain reaction and
primers based on the published sequences. The sequence of forward primer
for Dbv21 was 50-CACCCTGGAAGTTCTGTTCCAGGGGCCCATGTTGCAGG
ACGCCGACCGAACCCGG-30 with the TOPO vector cloning site (shown in
bold letters) and a Precision Protease cleavage site (shown in underlined
letters) preceding the starting codon. The sequence of reverse primer for
Dbv21 was 50-CTAGCTCGAGTTACTCGGCTGCGTAGCGAATGAC-30, with
the engineered stop codon TAA. The sequence of forward primer for Orf2*
was 50-CACCCTGGAAGTTCTGTTCCAGGGGCCCATGCCTCACGACCCCG
GTGCAACC-30, also with the TOPO vector cloning site (shown in bold letters)
and Precision Protease digestion site (shown in underlined letters) preceding
the starting codon. The sequence of reverse primer for Orf2* was 50-
CTAGCTCGAGTCAGCTGTCGTCGCTGCGGACGAC-30, with the engineered
stop codon TGA. Bacterial overexpression constructs for each Dbv21 and
Orf2* were created, with amino terminal polyhistidine affinity tags, with the
TOPO cloning system (Invitrogen).
The overexpression plasmids were individually transformed into
Escherichia coli strain BL21star and selected on LB-agar plates containing
50 mg kanamycin ml1. Individual colonies were diluted into 5ml of LB contain-
ing the antibiotic, grown for 5 hr at 37C, and then used to inoculate 1 l of LB
medium containing 50 mg kanamycin ml1. Following growth at 37C until the
optical density at 600 nm reached 0.5, protein productionwas inducedwith the
addition of 0.5 mM isopropyl-a-D-thiogalactopyranoside, and the cells were
further grown overnight at 18C. Bacterial cells were pelleted by centrifugation
(40003g for 30min) and resuspended in 100mMKCl, 20mMTris-HCl (pH8.3),
and 10% glycerol. The resuspended cells were disrupted by multiple passes
through an Avestin C5 Emulsiflex French press cell, and insoluble aggregates
and cellular debris were removed by centrifugation (15,000 3 g for 1 hr).
Recombinant Dbv21 or Orf2* was purified from the above-clarified superna-
tant by virtue of the amino terminal polyhistidine tag with a Talon resin (Clon-
tech) column charged with nickel sulfate. Following elution from the nickel
affinity resin, the polyhistidine tag was removed with Precision Protease (final
concentration 1 mg/ml). The protein was further purified by anion exchange
(5 ml HiTrap Q; G.E. Healthcare) and size-exclusion chromatography (Super-
dex 75 16/60; G.E. Healthcare) prior to crystallization. Selenomethionine incor-
porated Orf2* was produced by the method of van Duyne et al. (1993) and
purified in the same manner as described above. The purity of the protein
sample was greater than 95%, as judged by SDS-PAGE.
Crystallization
Crystals of both Dbv21 and Orf2* were grown by the hanging drop vapor dif-
fusion method. For crystallization of Dbv21, 1.5 ml protein (10 mg/ml) was
mixed with 1.5 ml precipitant solution containing 0.2 M magnesium acetate,
0.1 M sodium cacodylate (pH 6.5), and 12% polyethylene glycol 12,000. The
mixture drop was equilibrated over a well containing the same precipitant so-
lution at 8C, and crystals reached their maximum size after 3 days. For crys-
tallization of Orf2*, 1.3 ml protein (18mg/ml) wasmixedwith precipitant solution
containing 0.17 M sodium acetate, 0.085 M sodium cacodylate (pH 6.5), 18%
polyethylene glycol 8,000, and 15% glycerol. The mixture was equilibrated
over a well containing the same precipitant solution at 8C, and crystals
reached their maximum size after 5 days. Selenomethionine-incorporated
Orf2* was crystallized under the same conditions, except the protein concen-
tration was decreased to 12 mg/ml. Cocrystals of Orf2*-decanoic acid and
Orf2*-octanoic acid were grown under conditions similar to that of the unli-
ganded protein, but with the inclusion of with 10 mM ligand in the crystalliza-
tion drop. In order to obtain crystals of zinc-inhibited Orf2*, crystals were
soaked overnight in precipitant solution containing 10 mM zinc chloride. Crys-
tals of Dbv21 were step-wise equilibrated with incremental concentrations of
ethylene glycol up to a final concentration of 30% prior to vitrification in liquid
nitrogen. All crystals of Orf2* were grown under conditions suitable for cryo-
preservation, and were vitrified by direct immersion into liquid nitrogen.
Phasing and Structure Determination
A four-fold redundant data set was collected from crystals of selenomethio-
nine-substituted Orf2* at the selenium absorption edge, to a limiting resolution
of 1.6 A˚ (overall Rmerge = 4.3; I/s(I) = 4.8 in the highest-resolution shell) utilizing
a Mar 300 CCD detector (LS-CAT, Sector 21 ID-D; Advanced Photon Source,
Argonne, IL). The structure of Orf2* was solved by single-wavelength15, 533–545, June 2008 ª2008 Elsevier Ltd All rights reserved 543
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substituted methionine residues and one zinc ion per monomer. Data were
indexed and scaled with the HKL2000 package (Otwinowski et al., 2003).
Selenium sites were identified with the program, HySS, and the heavy atom
substructure was imported to SHARP for maximum likelihood refinement
and phase calculation (Bricogne et al., 2003), yielding an initial figure of merit
of 0.37 to 1.77 A˚ resolution. Solvent flattening and phase extension to 1.6 A˚
resolution with the program, DM, further improved the quality of the initial
map (figure of merit = 0.90) and permitted most of the main chain and 75%
of the side chain residues to be automatically built with ARP/wARP (Perrakis
et al., 1997). Crossvalidation used 5% of the data in the calculation of the
free R factor (Kleywegt and Brunger, 1996). The remainder of the model was
fitted with XtalView (McRee, 1999) and further improved by rounds of refine-
ment with REFMAC5 (Murshudov et al., 1997, 1999) and manual building.
In order to confirm the identity of the bound metal, an X-ray fluorescence
scan was conducted on crystals of native Orf2* at wavelengths near the ab-
sorption edge for zinc (LS-CAT, Sector 21 ID-D; Advanced Photon Source).
The scan yielded an absorption spectrum characteristic of zinc, and a full
360 of data were collected at the peak energy level at a wavelength corre-
sponding to the K absorption edge for zinc (l = 1.2782 A˚). Anomalous differ-
ence Fourier maps calculated with Bijvoet amplitudes from this data set and
phases from the final refined model of Orf2*, minus the zinc atom, reveal a
significant peak (> 8s) at a position corresponding to the zinc.
The structure of native Dbv21 was determined to 2.1 A˚ resolution by molec-
ular replacement (McCoy, 2007) with the refined coordinates of the SeMet
Orf2* structure as a search probe. Multiple rounds of manual model building
with XtalView (McRee, 1999) were interspersed with refinement with RE-
FMAC5 (Murshudov et al., 1997, 1999) to complete structure refinement. De-
spite extensive manual rebuilding and refinement, residues in the capping loop
region, bridging Arg-101 through Ala-125, remain ill defined and have not been
modeled in the structure. As a consequence of the mobility of the residues in
the capping loop, their contribution to scattering is minimal, as reflected by the
fact that the free R factor of 25% for this structure is within the range of expec-
tations for a 2.1 A˚ resolution structure.
The cocrystal structures of zinc inhibited Orf2* and the Orf2*-decanoic acid
complexwere also determined, each to 2.0 A˚ resolution, bymolecular replace-
ment with the refined coordinates of the SeMet Orf2* structure as a search
probe, and refined by the procedures detailed above. Crossvalidationwas rou-
tinely used throughout the course of model building, as was refinement with
5% of the data in the calculation of the free R factor (Kleywegt and Brunger,
1996). For each of the structures, stereochemistry of the model wasmonitored
throughout the course of refinement with PROCHECK (Laskowski et al., 1996).
Limited Proteolysis
Orf2* was purified and the polyhistidine affinity tag was removed, as detailed
above. Protein samples, at a concentration of 1 mg/ml as determined by the
Bradford method, were incubated with a substoichiometric concentration of
chymotrypsin (enzyme to protease ratio of 500:1) in the presence or absence
of 5-fold excess of purified teicoplanin. At the defined time intervals, an aliquot
of the reaction (20 ml) was mixed with an equal volume of sample buffer con-
taining 2%SDS and incubated at 95C in order to inactivate the protease. After
completion of all of the digests, 15 ml of the quenched reaction at each time
interval was resolved on a 12% Tris-SDS polyacrylamide gel. The resultant
digestion pattern was visualized by staining with Coomassie blue.
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